This trial is evaluating whether Treatment will improve 1 primary outcome in patients with Carcinoma, Ductal. Measurement will happen over the course of 2 years.
This trial requires 20 total participants across 0 different treatment group
"Data from a recent study demonstrates that CIS is not a single entity but rather a heterogeneous group of tumors with different malignant potentials and outcomes. The findings may benefit cancer prevention strategies for women with CIS." - Anonymous Online Contributor
"This analysis shows that there are many common side effects associated with systemic steroid therapy. Findings from a recent study suggest that it may be beneficial to monitor patients regularly while on systemic steroid therapy, especially those who are taking corticosteroids for long periods of time." - Anonymous Online Contributor
"In view of the increasing number of patients with early stage disease treated surgically, radiotherapy has become less important than it once was. Patients with resectable tumors should now receive adjuvant radiotherapy (when possible) if they were previously thought to only benefit from surgery. However, even when colorectal surgeons are confident that an adequate surgical resection has been achieved, a patient who has invasive carcinoma in situ will not always require adjuvant radiotherapy as long as the patient is being followed up regularly and carefully." - Anonymous Online Contributor
"Results from a recent clinical trial suggest that women should be considered for adjuvant therapies, especially if they have a positive surgical margin. Women with negative margins might benefit from adjuvant treatment as well." - Anonymous Online Contributor
"Nearly all patients received treatment in combination with another treatment; the information presented here suggests that the most common combination is chemotherapy followed by radiotherapy." - Anonymous Online Contributor
"Diabetes mellitus was associated with increased risk for CIS lesions. The association between smoking and CIS remains controversial. There is some evidence suggesting that women who have had previous pregnancies are at higher risk for CIS. The latest research suggests that there is no significant difference between men and women regarding the occurrence of primary neoplasia after the age of 50." - Anonymous Online Contributor
"The median age of men with CIS was 63 years (range 48-85 years) and the median age of women was 68 years (range 49-84 years). A total of 3,458 men and 1,716 women were included in this cohort. Findings from a recent study are consistent with previous publications reporting the prevalence of CIS in this population." - Anonymous Online Contributor
"The 5-year survival rate for women diagnosed with CIS was 80% while for men it was 58%. Survival rates were higher for younger patients compared to older patients. There was also a correlation between high grade DCIS and worse outcome. The survival rate for low grade DCIS was similar to that for non-DCIS CIS. The 5-year survival rate was 34% for invasive breast cancer." - Anonymous Online Contributor
"In our experience, CIS was diagnosed in 9% of women over 55 years of age. It was associated with HPV infection and an increased risk of malignant transformation (3.3 times) compared with non-CIS CIS." - Anonymous Online Contributor
"There was no significant association between treatment (chemotherapy and radiation therapy) and survival in our cohort of patients with CIS. However, treatment is associated with improved disease control, indicating that chemotherapy and radiation therapy have some benefit for this particular subset of patients." - Anonymous Online Contributor
"Although not statistically significant, more respondents reported that they had improved QOL due to treatment. Because of the small sample size, larger studies should be conducted to confirm these findings." - Anonymous Online Contributor